Specify a stock or a cryptocurrency in the search bar to get a summary
Vimian Group AB
VIMIANVimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden. Address: Riddargatan 19, Stockholm, Sweden, 11457
Analytics
WallStreet Target Price
534.22 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures VIMIAN
Dividend Analytics VIMIAN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History VIMIAN
Stock Valuation VIMIAN
Financials VIMIAN
Results | 2019 | Dynamics |